International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7866753
Original Article
HELLP Syndrome: It’s Maternal and Foetal Outcome
 ,
 ,
 ,
Published
April 26, 2023
Abstract
Objective: To study maternal and foetal outcome in HELLP syndrome. Study design: The present study was a hospital based prospective observational study to find out maternal and perinatal outcome in HELLP syndrome. Subjects & methodology: This study was conducted at the Department of Obstetrics and Gynaecology, Government medical college, Aurangabad during six months (from July 2022 to December 2022) with more than 28 weeks gestation,150 patients of HELLP syndrome were studied. Most common age group is 21-25 years(40.67%), followed by 26-30 years(30.67%). All available detailed history, clinical data, detailed laboratory investigation were studied and characterized by Tennessee and Mississippi classification for better analysis of complications and outcome in HELLP syndrome. Conclusion: HELLP syndrome is a severe variant and dreadful complication of Preeclampsia and Eclampsia, it needs early diagnosis and timely intervention in the form of termination of pregnancy to arrest further progress of pathophysiology leading to complication.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
192 Views
226 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved